Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01821690 · ClinicalTrials.gov registry record · Phase 4
Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT01821690 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 81 participants.
The verdict
NCT01821690, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to improve behavior control displayed by persons with traumatic brain injury by assessing effectiveness of treatments for post-TBI irritability and aggression.
Interventions
- DRUG Placebo
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-05-15 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01821690
The ClinicalTrials.gov registry entry for NCT01821690 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01821690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01821690 about?
NCT01821690 is a clinical study titled "Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression". The purpose of this study is to improve behavior control displayed by persons with traumatic brain injury by assessing effectiveness of treatments for post-TBI irritability and aggression.
What is the current status of trial NCT01821690?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2013-05-15. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT01821690?
The interventions under investigation include: Placebo (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT01821690?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.